Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.60    -0.10 (-3.70%)
Bid:
2.60
Ask:
2.66
Spread: 0.06 (2.308%)
Market Cap: £2.68m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Positive development on case

12 Jan 2026 14:07

RNS Number : 5649O
Litigation Capital Management Ltd
12 January 2026
 

12 January 2026

Litigation Capital Management Limited

("LCM" or the "Company")

Positive development on international arbitration claim

 

Litigation Capital Management Limited ("LCM"), an alternative asset manager specialising in dispute financing solutions internationally, announces a positive development in the international arbitration claim against the Republic of Poland (Poland) that it funded. As previously announced on 8 October 2024, the funded party achieved a successful outcome, securing two separate awards - one under the Energy Charter Treaty (ECT) of £252 million plus interest; and one under the Australia-Poland Bilateral Investment Treaty (BIT) of £183 million plus interest. There is no double compensation meaning that total damages cannot exceed £252 million plus interest.

Poland commenced set-aside proceedings in Singapore (ECT) and London (BIT) to attempt to annul the original awards. The Singapore proceedings recently concluded and the Singapore court rejected in its entirety Poland's application to set-aside the ECT award. Poland has a right to an appeal and such an appeal must be filed by 6 February 2026. We anticipate an appeal will be filed and expect the Singapore court to resolve such an appeal in the second half of 2026.

LCM has invested into this case alongside Fund I investors with the total investment being US$11.3m with US$2.8 million coming from LCM's own balance sheet and US$8.5 million from Fund I. LCM's returns are calculated as a rising multiple of invested capital over time plus interest. LCM's contractual entitlement on this case currently stands at approximately US$71.9 million with US$18.0 million of that flowing to LCM shareholders and US$53.9 million flowing to Fund I investors. LCM does not anticipate earning a performance fee from Fund I investors on this case as a result of previously announced adverse case results impacting Fund I. 

Enquiries

Litigation Capital Management

Patrick Moloney, Chief Executive Officer

David Collins, Chief Financial Officer

Cavendish (Nomad and Broker) 

Tel: 020 7220 0500

Jonny Franklin-Adams and Isaac Hooper (Corporate Finance)

Tim Redfern (Corporate Broking)

 

www.lcmfinance.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBTMITMTMBBAF
Date   Source Headline
22nd Sep 20207:00 amRNSFinal Results
10th Sep 20202:57 pmRNSHolding(s) in Company
8th Sep 20207:00 amRNSNotice of Results
24th Aug 20207:00 amRNSFunding of Corporate Portfolio Transaction
18th Aug 20207:00 amRNSAppointment of Non-Executive Director
13th Aug 20207:16 amRNSDisputes Finance Facility with Global Law Firm
10th Jul 20207:04 amRNSMarket Update
6th Jul 20204:40 pmRNSSecond Price Monitoring Extn
6th Jul 20204:35 pmRNSPrice Monitoring Extension
2nd Jul 202010:42 amRNSBoard Updates
26th May 20207:00 amRNSAustralian Regulation of Litigation Funders
22nd May 20204:41 pmRNSSecond Price Monitoring Extn
22nd May 20204:36 pmRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSConclusion of Joint Venture Arrangement
3rd Apr 20207:08 amRNSManagement Update and Corporate Reorganisation
24th Mar 20207:00 amRNSFinal closure of US$150 million fund
23rd Mar 20207:41 amRNSDirector/PDMR Shareholding
17th Mar 20207:00 amRNSHalf-year Report
10th Mar 20207:00 amRNSFirst close of a new US$150 million fund
13th Feb 20207:00 amRNSNotice of Results
6th Feb 202012:07 pmRNSSecond Price Monitoring Extn
6th Feb 202012:02 pmRNSPrice Monitoring Extension
20th Dec 20198:04 amRNSCase Investment Settlement Update
16th Dec 20194:41 pmRNSSecond Price Monitoring Extn
16th Dec 20194:35 pmRNSPrice Monitoring Extension
11th Dec 201912:07 pmRNSSecond Price Monitoring Extn
11th Dec 201912:02 pmRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSCapital Markets Event and Third-Party Fund Update
2nd Dec 20197:00 amRNSNotice of Dividend Currency Exchange Rate
21st Nov 20199:30 amRNSHolding(s) in Company
21st Nov 20198:25 amRNSResult of AGM
18th Nov 201912:23 pmRNS2019 Annual Report & Accounts
12th Nov 201912:07 pmRNSSecond Price Monitoring Extn
12th Nov 201912:02 pmRNSPrice Monitoring Extension
6th Nov 20197:00 amRNSAppointment of Joint Broker
1st Nov 201911:23 amRNSIncentive Awards
16th Oct 20198:00 amRNSNotice of Annual General Meeting
30th Sep 201912:00 pmRNSHolding(s) in Company
30th Sep 201912:00 pmRNSHolding(s) in Company
13th Sep 20193:01 pmRNSHolding(s) in Company
10th Sep 20197:00 amRNSFinal Results
2nd Sep 20197:30 amRNSNotice of Results
17th Jul 201910:42 amRNSHolding(s) in Company
28th Jun 201911:44 amRNSConditional Settlement of Litigation Project
13th Jun 20197:00 amRNSFunding of Corporate Portfolio Transaction
3rd Jun 20198:59 amRNSNotice of Dividend Currency Exchange Rate
28th May 20197:42 amRNSCourt Approval Settlement and Pipeline Update
8th Apr 201910:14 amRNSHolding(s) in Company
5th Apr 201912:18 pmRNSHolding(s) in Company
1st Apr 20199:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.